| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
|
Cancer Res
|
2007
|
2.15
|
|
2
|
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
|
ACS Chem Neurosci
|
2010
|
1.46
|
|
3
|
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
|
Drug Metab Dispos
|
2010
|
1.41
|
|
4
|
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
|
Cancer Res
|
2011
|
1.34
|
|
5
|
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane.
|
Biochemistry
|
2007
|
1.33
|
|
6
|
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
|
Biochem Pharmacol
|
2007
|
1.19
|
|
7
|
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.
|
Drug Metab Dispos
|
2013
|
1.18
|
|
8
|
ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions.
|
Curr Drug Deliv
|
2007
|
1.18
|
|
9
|
New inhibitors of ABCG2 identified by high-throughput screening.
|
Mol Cancer Ther
|
2007
|
1.18
|
|
10
|
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
|
Mol Cell Biochem
|
2006
|
1.16
|
|
11
|
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
|
Mol Cancer Ther
|
2006
|
1.14
|
|
12
|
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
|
Mol Cancer Ther
|
2007
|
1.13
|
|
13
|
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
|
Biochem Pharmacol
|
2008
|
1.12
|
|
14
|
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections.
|
Mol Biosyst
|
2005
|
1.10
|
|
15
|
Botryllamides: natural product inhibitors of ABCG2.
|
ACS Chem Biol
|
2009
|
1.05
|
|
16
|
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
|
Cancer Res
|
2010
|
1.04
|
|
17
|
Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis.
|
Biochemistry
|
2003
|
1.04
|
|
18
|
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
|
Mol Cancer Ther
|
2012
|
1.03
|
|
19
|
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.
|
Mol Cancer Ther
|
2007
|
1.02
|
|
20
|
Alanine scanning of transmembrane helix 11 of Cdr1p ABC antifungal efflux pump of Candida albicans: identification of amino acid residues critical for drug efflux.
|
J Antimicrob Chemother
|
2005
|
1.01
|
|
21
|
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
|
Proc Natl Acad Sci U S A
|
2013
|
0.96
|
|
22
|
Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals.
|
Antimicrob Agents Chemother
|
2009
|
0.94
|
|
23
|
Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.
|
PLoS One
|
2013
|
0.88
|
|
24
|
Conserved Asp327 of walker B motif in the N-terminal nucleotide binding domain (NBD-1) of Cdr1p of Candida albicans has acquired a new role in ATP hydrolysis.
|
Biochemistry
|
2006
|
0.87
|
|
25
|
The amino acid residues of transmembrane helix 5 of multidrug resistance protein CaCdr1p of Candida albicans are involved in substrate specificity and drug transport.
|
Biochim Biophys Acta
|
2009
|
0.86
|
|
26
|
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.
|
Cancer Chemother Pharmacol
|
2006
|
0.85
|
|
27
|
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
|
BJU Int
|
2008
|
0.84
|
|
28
|
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
|
Mol Pharmacol
|
2009
|
0.84
|
|
29
|
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
|
Biochem Pharmacol
|
2012
|
0.84
|
|
30
|
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
|
Cancer Chemother Pharmacol
|
2009
|
0.82
|
|
31
|
Divergent signature motifs of nucleotide binding domains of ABC multidrug transporter, CaCdr1p of pathogenic Candida albicans, are functionally asymmetric and noninterchangeable.
|
Biochim Biophys Acta
|
2010
|
0.80
|
|
32
|
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
|
PLoS One
|
2013
|
0.80
|
|
33
|
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.
|
Bioorg Med Chem Lett
|
2012
|
0.79
|
|
34
|
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
|
Invest New Drugs
|
2015
|
0.75
|